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Postmenopausal women have increased risk of metabolic diseases including non-
alcoholic fatty liver disease (NAFLD). Hormone replacement therapies (HRT) reverse some of 
the risk factors associated with metabolic disease but increases the risk of reproductive cancers. 
Novel and synthetic estrogens may have the beneficial effects of HRT on metabolic health but do 
not increase the risk of cancers. The objective of these studies is to evaluate the effects of novel 
and synthetic estrogens on metabolism by analyzing transcriptomic, metabolomics, and 
microbiome data in mouse and cell line models. Additionally, a potential mechanism of 
interaction between estrogens and the gut microbiome is explored.  
 Pathway preferential estrogen 1 (PaPE-1) is a promising novel estrogen receptor ligand 
that has been shown to favorably target tissues through selective activity. Though its effects on 
weight gain and fat accumulation have been previously investigated, its effects on liver 
transcriptome and plasma metabolites have yet to be determined. We use several genomics and 
postgenomics technologies to characterize the effects of various estrogens on the health of the 
liver. Additionally we tested the effects of PaPE-1 on two different mouse models: diet induced 
obesity (DIO) and leptin deficient (ob/ob) mice. PaPE-1 significantly decreased liver weight in 
both DIO and ob/ob models. H&E staining show that lipid accumulation decrease in animals 
who receive PaPE-1 treatment and this phenotype is also confirmed in HepG2 cells. Integrated 
pathway analysis using transcriptomics and metabolomics identified lower inflammation and 
fatty acid metabolic pathways to be modulated by PaPE-1 treatment. Our results show that PaPE-
1 showed significant changes in inflammation and lipid synthesis and deposition-related 
metabolic pathways in two different mouse models that simulate metabolic dysfunction due to 
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loss of estrogen cycling in combination with genetic background (ob/ob mice) and high-fat diet. 
In both models PaPE-1 is protective against steatosis and NAFLD. 
Bazedoxifene and conjugated estrogens (CE+BZA) combination has been shown to 
prevent visceral adiposity and weight gain after menopause. However, its interaction with the 
liver and prevention of steatosis has yet to be examined. As reported in previous studies, 
CE+BZA combination is very effective at preventing ovariectomy-induced weight gain in mice 
fed a high-fat diet (HFD). H&E and Oil Red O staining show that lipid droplet size is 
significantly reduced in CE+BZA treated animals after ovariectomy and HFD. Additionally, 
CE+BZA induces unique liver transcriptomic profiles compared to estradiol, conjugated 
estrogens alone, or bazedoxifene alone. Integrated pathway analysis shows that the most 
significant pathways influenced are associated with lower rates of inflammation and unsaturated 
fatty acid biosynthesis. These results point to overall benefits to liver health by CE+BZA 
treatment.  
Recent advances have enriched our understanding of the microbiome and have provided 
evidence that estrogens and gut microbiota might synergize to influence pathophysiologic 
conditions such as NAFLD. A better understanding of underlying mechanisms in estrogen and 
microbiota crosstalk might offer new approaches to influence this crosstalk and improve 
metabolic outcomes. Microbiome analysis in animals who received CE+BZA treatment show 
that there are no significant differences in the diversity of bacteria genera in the gut compared to 
vehicle treated animals. To identify changes in different genera of bacteria that are associated 
with weight gain after ovariectomy, we utilized Extended Random Forest (ERF) approach. This 
analysis identified Dehalobacteria, Akkermansia, and Anaerotruncus genera. There may be a 
potential for these genera to influence estrogen metabolism in the body by increasing the half-life 
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of estrogens in the body. Further future studies will be performed to assess various metabolic 
activities associated with these bacteria that might influence half-life and fate of synthetic 
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CHAPTER 1: INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world 
and encompasses a spectrum of liver diseases including fat accumulation (steatosis), 
inflammation, fibrosis or non-alcoholic steatohepatitis (NASH), and cirrhosis [1]. Steatosis is 
considered the mildest state of the disease, and will evolve into NASH in 20-25% of cases [2]. 
Cirrhosis is considered the most severe state and will develop in 20% of patients with NASH [2]. 
NAFLD rates are steadily increasing and is strongly associated with obesity, which has become a 
worldwide epidemic [1]. Currently, there are no pharmacological drugs approved by the FDA for 
the treatment of NAFLD or NASH and lifestyle interventions are the only recommended 
therapies for these diseases. Given the rates and prevalence of the disease, NAFLD has become a 
public health burden.  
The pathogenesis of NAFLD is complex and unknown, however, there are significant 
links between NAFLD and abnormal lipid metabolism as seen in obesity and metabolic 
syndrome. In fact, the prevalence of NAFLD increases with increasing body mass index (BMI) 
with the rates of steatosis and steatohepatits at 65% and 20% respectively in obese individuals 
(BMI 30.0-39.9 kg/m
2
) and 85% and 40% respectively in extremely obese patients (BMI≥40 
kg/m
2
) [3]. The prevalence of NAFLD is about 69% in patients with type 2 diabetes mellitus 
(T2DM) [4]. Risk factors include dietary fat consumption, insulin resistance, elevated serum free 
fatty acids, excess visceral adiposity, and pro-inflammatory markers among others [5]. These 
risk contribute to the “two-hit” hypothesis of NAFLD pathogenesis, which suggests that NAFLD 
is caused by two major factors: the accumulation of excessive hepatic fat and oxidative stress [6-





Chronic overconsumption and a “western diet”, which is high in saturated fat and sugar, 
leads to overeating and obesity. The present Dietary Guidelines reveal that more than 35% of 
daily energy consumed by Americans is from fat, particularly saturated fats, and added sugar [9]. 
Excess consumption of saturated fat and sugar not only contributes to body fatness but also to the 
progression of chronic, low-level inflammation, adversely impacting hepatic health in general 
and aggravating chronic diseases such as diabetes and hepatocellular carcinogenesis. Cancer risk 
increases with the progression into NASH, which accounts for 20-25% of patients with NAFLD 
[2, 10]. Saturated fatty acids are a poor source of energy, since they are not the priority substrate 
for β-oxidation, and tend to be directed toward storage [11].  In liver, saturated fatty acids can 
increase endoplasmic reticular stress and free radical production in mitochondria, which 
promotes the development of NASH [12].  Moreover, fructose, which is a component of sucrose, 
is a highly lipogenic nutrient, enhancing hepatic lipid accumulation through the de novo 
lipogenesis pathway [13]. Therefore, the Westernized diet is able to disrupt lipid homeostasis 
and oxidative balance in the liver and worsen the development of NAFLD. 
Previous studies showed that estrogens have a protective effect against NAFLD. 
Menopause is defined as the absence of menses for 12 consecutive months and is marked by an 
increase in serum follicle-stimulating hormone (FSH) and decrease in estradiol (E2) and inhibin 
[14, 15]. The changes in endocrine hormone levels can increase risk of metabolic symptoms such 
as insulin resistance, hyperlipidemia, and visceral fat accumulation [16]. Many of these 
symptoms lead to metabolic diseases such as obesity and NAFLD [16]. At premenopausal age, 
women have a lower NAFLD risk compared to men whereas after menopause, women have the 
same risk as men [17, 18]. Population studies have shown that women without NAFLD have 
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higher levels of serum estradiol compared to women with NAFLD (p=0.001) [19, 20]. NAFLD 
appears to be more correlated with later menopausal stages with higher prevalence in late 
menopausal transition, 60 days or more after menses cessation [20]. This suggests that 
postmenopausal women are a target group with an increased risk for NAFLD. 
Hormone replacement therapy (HRT) is used to treat common symptoms of decreased 
estrogens as in postmenopausal women. Current HRT typically consists of an estrogen or 
estrogen in combination with a progestin, and may be taken to relieve hot flashes or low bone 
mass. Though the initial reason a woman would take HRT are usually not metabolic, there are 
many metabolic benefits to HRT including reversing insulin resistance and glucose homeostasis 
[21, 22]. HRT has also been shown to favorably influence liver enzymes and potentially lower 
liver fat accumulation in women with type 2 diabetes [23]. However, though HRT has many 
metabolic benefits, they have been shown to increase risks of certain cancers including breast 
cancer and endometrial cancers [24-27]. Therefore, it is essential to find safer alternatives to 
HRT such as novel and synthetic estrogens that can maintain the health of non-reproductive 
tissues without stimulating reproductive tissues.  
In order to better understand the effects of different estrogens on the liver, metabolism 
involving the liver and potential microbiome interactions must be examined. The gut 
microbiome plays a critical role in metabolism. In a normal gut, microbiota can benefit human 
health by digesting resistant starch and fibers, synthesize vitamins, provide immunity, and 
prevent pathogen colonization [28]. However, in a disrupted gut microbiome, or dysbiosis, 
bacterial metabolites and bacterial cell components can reduce intestinal epithelial integrity and 
access the liver through the portal vein (Fig 1.1). These microbial byproducts can contribute to 
inflammation, liver steatosis, and injury ultimately leading to NAFLD [29]. As such, to 
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determine if an estrogenic treatment is beneficial to liver health, not only should host metabolic 
pathways be analyzed, but the gut microbiome as well. 
In this investigation, the interaction between estrogens and liver health and the 
microbiome is explored. Several “–omics” technologies, such as transcriptomics and 
metabolomics are used in various models to give a holistic mechanistic view. Two studies focus 
particularly on the effects of synthetic estrogens on the liver whereas the third study examines 
more direct effects of the microbiome. This research advances our understanding on the effects 
of synthetic estrogens PaPE-1 and CE+BZA on the gut-liver axis and enhances our 





ESTROGEN REGULATION IN POSTMENOPAUSAL METABOLIC SYNDROME 
2.1 THE RISING INCIDENCE OF METABOLIC SYNDROME 
Estrogens are steroid hormones that bind to and activate their cognate receptors, ERα and 
ERβ. These hormones have been shown to improve symptoms associated with obesity. Estrogens 
regulate adipocyte metabolism and cause remodeling of particular adipose depots as seen in 
postmenopausal women, where lower estrogen levels cause fat remodeling from the hips and 
thighs to the abdomen, compared to premenopausal women [30].  
The “microbiota” consists of a large population of microorganisms present in and on the 
body. One of the largest collections of these microorganisms is found in the gastrointestinal tract 
where they act symbiotically with the human body to ferment dietary fibers, aid in digestion and 
absorption, and protect against pathogens [31]. The diversity of this host-microbe interaction 
could allow it to be involved in a wide range of pathways that can affect human health, disease, 
and aging [31]. Emerging evidence is now showing that an interaction between estrogens and the 
microbiome may have an effect in mediating metabolic rate, body weight, and adiposity. In this 
Forum we will discuss current research linking metabolic syndrome, estrogens, and the 
microbiome. Furthermore, we will propose prospective and future research to improve the 
metabolic health of postmenopausal women.  
 
2.2 MECHANISMS OF METABOLIC REGULATION BY ESTROGENS  
In humans, there are three major estrogens endogenous to the human body. These are 
estrone (E1), 17β-estradiol (E2), and estriol (E3) with E2 being the most potent [32]. Estrogens 
are derived from cholesterol in the body and catalyzed by the P450 aromatase [32]. E2 has the 
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greatest affinity for estrogen receptors and a higher bioactivity [33]. Several tissues are able to 
generate estrogens in humans including the reproductive organs of both males and females, the 
liver, osteoblasts, muscle cells, skin, and adipose tissue [34]. In premenopausal women, the 
ovaries produce the majority of the estrogen released into circulation [32]. However, after 
menopause, ovaries stop functioning, dramatically decreasing the concentrations of estrogen in 
the body. However, estrogen synthesis continues in adipose tissue and adipose tissue-derived 
estrogen accounts for most of the circulating estrogens in postmenopausal women [35]. In a 
longitudinal study, trends in obesity and hormone levels in women differed by menopausal status 
[36]. Obese and overweight women had significantly lower concentrations of estradiol than non-
obese women before menopause however, this trend is opposite after menopause where obese 
and overweight women have higher estradiol levels than non-obese women. High estrogen levels 
could be attributed to the greater amounts of adipose tissue found in obese women.  
Estrogens regulate adipocyte metabolism and cause remodeling of particular adipose 
depots which are clearly different between premenopausal women and men compared to post-
menopausal women [34]. Estrogens can decrease lipogenesis by inhibiting lipoprotein lipase 
(LPL) that directly decrease lipid deposition [37]. In an in vitro study, mouse adipocyte cell lines 
showed that fat accumulation depended on the expression of LPL as E2 treatment decreased LPL 
mRNA, which blocked lipid deposition in turn. LPL downregulation is possibly mediated by an 
estrogen-response suppressive element in the LPL promoter gene. LPL is responsible for 
hydrolyzing triglycerides and facilitates adipose tissue storage. Increased levels of LPL have 
been shown in adipose tissue of obese human patients [38]. In obese women, plasma estradiol 
activity has a strong negative correlation with LPL activity in adipose and postheparin plasma. 
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These studies seem to suggest that estrogen may directly influence fat storage and limit fat 
accumulation in adipocytes by decreasing LPL action.  
In ovariectomized mice fed a high fat diet, E2 administration improved glucose tolerance 
and insulin sensitivity. In the event of decreased estrogen production, as in after menopause or 
following ovariectomy, body weight increases, which can be negated by estradiol treatment [39-
41]. It appears that estrogens may impact other hormones that regulate body weight homeostasis. 
In terms of glucose homeostasis, aromatase knockout mice showed signs of hepatic insulin 
resistance by decreasing Akt phosphorylation in the liver [41]. However, with the treatment of 
estrogen, Akt phosphorylation of aromatase knockout mice was restored reversing these effects. 
Akt is a key mediator in the insulin signaling pathways. Therefore, decreasing its 
phosphorylation by lowering plasma estrogen concentrations in aromatase knockout mice would 
severely impact the downstream pathways [41]. Ultimately, estradiol treatment in estrogen 
deficient mice improved insulin sensitivity by increasing the phosphorylation of the key 
mediators in insulin signaling [41, 42]. 
The levels of adipokines such as adiponectin and leptin may be affected by estrogen 
concentrations [43]. Adiponectin is prodced by adipocytes and are involved in fatty acid 
metabolism and glucose regulation [44]. Levels of adiponectin are inversely correlated to the 
concentrations of plasma estrogen levels in females even though females have higher overall 
concentrations of plasma adiponectin than males do. However, this paradox may be attributed to 
other hormones such as testosterone that results in the dimorphic differences in adiponectin 
levels. Estrogen may also increase leptin sensitivity by controlling the expression of their 
receptors [45]. In ovariectomized female rats injected with extraneous leptin, responsiveness to 
the anorexigenic effects of leptin were reduced and these mice had much higher food intake and 
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a greater increase in body weight than intact females. As leptin inhibits hunger and influences 
satiety, estrogens can aid in energy regulation and food intake to control obesity through this 
mechanism. Other adipokines such as tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-
6) were also shown to be increased following estrogen treatment of aromatase knockout mice 
[41]. Endogenously, estrogen increases leptin production in rats and humans [45]. 
Supplementation of estrogen in postmenopausal women caused an increase in circulating leptin 
levels. These studies show that estrogens control the levels of different adipokines associated 
with glucose and lipid metabolism which may lead to the higher instances of obesity after 
menopause when estrogen levels decline. 
 
2.3 MECHANISMS OF GENE REGULATION BY ESTROGENS  
Estrogens work with several epigenetic regulators to control gene expression events. As a 
ligand activated transcription factor ERs are activated by estrogens that enable interactions with 
the coactivators or corepressors. The action of ERα appears to be influenced by several 
coactivators including SRC1, SRC2, p300, and CARM1 [46]. Coactivators such as these will 
bind to the ERα as they are unable to bind the DNA directly. They increase transcription rate by 
recruiting and stabilizing the basal transcription machinery. 
Since estrogen receptors are ligand-mediated nuclear receptors, they are bound to 
response elements located in the promotor region of target genes. ERα can modulate gene 
transcription through direct association with the target gene chromatin [47]. The receptors are 
associated with corepressors when there is an absence of estrogen. The association of the 
corepressor is considered the resting state of the nuclear receptor. However, when estrogen is 
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present, the corepressors dissociate and transcription is activated. Once this occurs, RNA 
polymerase II can easily associate to the promoter and mRNA is synthesized. 
Another mechanism of estrogen action could be through histone modifications at 
conserved lysine residues of histone tails. Most coregulatory complexes contain histone 
modifying enzymes. Multiprotein complexes including ERα may contain coactivators and 
histone modifying enzymes that migrate to the chromatin in response to hormone binding [48]. 
Histone modification by estrogen stimulation may include acetylation, phosphorylation, and 
methylation [49]. Coactivators of estrogen receptors such as SRC1 contain intrinsic histone 
acetyltransferase activity. Acetylated histones are associated with open chromatin leading to 
active transcription, which is reversed by histone deacetylases that halt transcription. Acetylation 
is therefore suggested to make DNA more accessible to transcription by exposing the DNA and 
allowing  RNA polymerase II transcriptional machinery to access these regions [50]. These 
coactivators with histone modification activities may modulate the transcription of genes related 
to fatty acid metabolism and storage.   
Estrogens regulate expression levels of several genes that are important for lipid 
deposition. FASN is fatty acid synthase which synthesizes fatty acids. Estradiol modulates FASN 
expression through downstream signaling and cross-talk in several transduction pathways [51]. 
In ovariectomized mice, FASN levels were increased, which were reversed by the administration 
of an estrogen receptor ligand. Estrogen also appears to upregulate α2A-adrenergic receptors in 
human adipose tissue which lowers the lipolytic response in subcutaneous adipose tissue of 
healthy women [52]. By upregulating these receptors only in subcutaneous adipose tissue and not 
in abdominal adipose tissue, fat accumulation is higher in subcutaneous areas. This may explain 
why females have higher deposits in these areas compared to the higher abdominal fat 
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accumulation n males. SREBP-1 is sterol regulatory element-binding protein 1 which is involved 
in glucose metabolism, fatty acid production, and cholesterol production. After ovariectomy, 
expression of SREBP-1c, one of the isoforms of the SREBP, was much higher than in intact 
mice [53], which suggests that estrogens may decrease the expression of SREBP-1 to prevent 
hepatic fat accumulation.  
Though epigenetic effects of estrogen receptors can mediate homeostasis and control fat 
accumulation, estradiol treatment after menopause often results in negative epigenetic effects. 
Most notable is the incidence of breast and endometrial cancers. Direct nuclear action of ERs and 
kinase cascades activated by extranuclear receptors changes histones modifications and gene 
expression, causing tumor progression [54]. Because of the potent effects of estradiol treatment, 
more research is needed to assess estrogenic activity and other estrogen receptor ligands that may 
regulate pathways that alleviate obesity without the detrimental effects such as tumor progression 
and cancer. 
 
2.4 INTERACTION OF MICROBIOTA AND ESTROGENS 
The microbiota composition was suggested to ameliorate symptoms associated with 
obesity. Insulin sensitivity in humans was improved by transferring gut microbiota from lean 
donors to those with metabolic syndrome [55]. Manipulating the gut microbiota composition 
with probiotic and prebiotics may also improve weight and fat mass development. Mice fed a 
high fat diet (HFD) had improved glucose-insulin homeostasis and attenuated weight gain when 
given Lactobacillus and Bifidobacterium probiotics, compared to mice fed a normal diet [56].  
Estrogen and the microbiota play major roles in obesity independent of each other. However, 
recent evidence suggests that estrogens and the microbiota may act together to regulate weight 
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gain and lipid deposition. Estrogen-like compounds, when consumed, may promote the 
proliferation and growth of certain types of bacteria. Soy isoflavones such as daidzein, genistein, 
and glycitin can significantly alter fecal bacterial community structure and composition in 
postmenopausal women by increasing the concentration of the beneficial gram-positive 
Bifidobacterium while suppressing Clostridiaceae, which can be the cause of several human 
diseases [57, 58]. Some bacteria also metabolize certain estrogen-like compounds or 
phytoestrogens like soy isoflavone to produce more biologically active forms that have high 
affinity for human ERs [59]. Diets that contain more phytoestrogens were shown to control 
weight gain [60], whereas diets with high gut microbial metabolites of phytoestrogen lignans 
were associated with a lower rate of being overweight and obese [60]. Some gut bacteria are 
known to metabolize phytoestrogens into O-desmethylangolensin (ODMA) and equol, which are 
structurally similar to mammalian estrogen [57, 58, 60]. Individuals who do not harbor bacteria 
that can produce ODMA are more likely to be obese than those who are producers [57]. 
Furthermore, more than 50% of obese individuals are equol non-producers [58]. Equol may aid 
in glycemic control and lower LDL levels, demonstrating the crucial role bacteria have on the 
activation of soy phytoestrogens in relation to obesity [60]. Thus, phytoestrogen metabolites may 
have a role in preventing aspects of metabolic syndrome. Recent studies showed that 
supplementation of the chalconoid isoliquiritigenin, a low-affinity ER ligand found in licorice 
root, improved ovariectomy associated weight gain and metabolic syndrome, but did not 
stimulate reproductive tissues [61]. It is currently unclear how isoliquiritigenin or any other low 
affinity estrogen supplementation would alter gut microbiota and blood metabolites.  
More recently, intestinal microbiota (IM) genes that are capable of producing estrogen 
metabolizing enzymes have been identified. These set of genes, or the “estrobolome”, implies a 
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potential for biomarker applications in several metabolic diseases [62]. Estrogens in the body are 
absorbed by the liver through first-pass metabolism, and biotransformed through methylation, 
hydroxylation, and conjugation into metabolites of varying potency for ERs (Fig. 2.1). The 
estrobolome could further alter these transformed estrogens. For example, some bacterial species 
have been identified with β-glucosidase activity. Increased estrogen metabolite concentration 
appears to be strongly associated with microbial diversity compared to parent estrogens present 
in fecal specimens [63]. Additionally, increased parent estrogen concentrations compared to 
estrogen metabolites have been associated with an increase in breast cancer risk [63]. Estrogen 
metabolite to parent estrogen ratio may be important to evaluate in obesity and other metabolic 
diseases as well. Collectively these data suggest gut microbiota as a potential biomarker for 
evaluating and preventing estrogen-associated pathologies. 
 
2.5 ESTROGEN AND MICROBIOTA CROSSTALK IN PATHOLOGIC CONDITIONS 
2.5.1 Type 2 Diabetes (T2D) and Inflammatory Disease 
The composition of gut microbiota differs in diabetic and non-diabetic subjects [64]. 
Microbial communities were suggested to contribute to the development of insulin resistance. 
Estrogens also regulate adipocyte derived hormones or adipokines. When misregulated, these 
adipokines play a role in low grade inflammation which triggers T2D [64].  
A HFD changes IM composition and increases the concentration of gram negative bacteria, 
which produce lipopolysaccharide (LPS), an endotoxin associated with inflammation in T2D 
[64]. Estrogens reduce LPS induced inflammation and decrease the concentration of pathogenic 
microbiota [64], though the exact mechanism is unclear. LPS production and increased 
inflammation drive other diseases such as non-alcoholic fatty liver disease (NAFLD). NAFLD is 
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strongly influenced by obesity and insulin resistance; obesity changes IM composition, leading 
to increased gut leakiness [65]. Endotoxin and cytokine passage into mesenteric blood together 
with increased free energy available due to increase metabolism of food by the IM lead to 
NAFLD [65]. Gut bacterial population is altered in subjects with NAFLD and certain bacterial 
overgrowths might play a role in disease development and progression. Thus, estrogens and 
probiotics may prevent NAFLD more effectively together.  
 
2.5.2 Breast Cancer 
Estrogens and ERs mediate the progression of breast, uterine, and endometrial cancers. In 
postmenopausal women, microbiota diversity that causes a higher level of circulating estrogens 
in the blood is associated with a higher risk of developing breast cancer. Decreased ratio of 
estrogen metabolites to parental compound and fecal microbiota diversity were shown to be 
associated with increased breast cancer risk in postmenopausal women [63]. 
Phyotestrogens are shown to possibly reduce the risk of developing cancer by activating 
ERs [66]. Resveratrol, daidzein, quercetin, and genistein, the most commonly studied 
phytoestrogens [66], are known to affect cell growth and proliferation and may prevent cancer 
development by promoting apoptosis or programmed cell death [66]. IM may also influence the 
progression of cancers since endotoxins from gram-negative bacteria may promote inflammation 
leading to cancer [67]. The gut flora of those with colorectal cancer differ from those without 
colorectal cancer suggesting that certain bacteria are found to be associated with cancer 
development and progression [68]. As bacteria in the gut can metabolize phytoestrogens and 
produce metabolites with an increased bioactivity [58], these bioactive compounds may be able 
to alter the microbial population and have anti-cancer properties [67]. However, there is little 
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Estrogens are key in maintaining homeostasis in healthy premenopausal individuals. 
When estrogen levels decrease with menopause, metabolic rate decreases, causing increased 
weight and obesity. However, we still do not know how certain estrogens may alter the 
microbiome to resemble normal weight phenotypes or how gut estrogenic byproducts produced 
by gut bacteria may act as ER ligands to mediate metabolic functions. It may be possible that the 
microbiota metabolize endogenous or dietary estrogens to produce novel ER ligands that can 
also be used to mitigate symptoms associated with menopause and obesity. Alternatively, the 
microbiota may be manipulated to produce less potent estrogens that could maintain metabolic 
function but reduce the risk of other diseases such as cancer. By identifying and analyzing other 
forms of estrogen that may be less potent and bind loosely to receptors, it may be possible to find 
more effective forms of estrogen replacement therapies. Treatment may also involve using 
microbiota therapies in conjunction with estrogen therapies that work independently or 





CHAPTER 3  
METABOLIC CHARACTERIZATION OF ESTROGENIC TREATMENT PaPE-1 
SHOWED BENEFITS IN LIVER HEALTH 
3.1 INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver 
disease in the United States and is characterized by histologic hepatitis in the absence of alcohol 
abuse [65]. Though simple steatosis is considered benign, steatosis of the liver can progress to 
nonalcoholic steatohepatitis (NASH) and cirrhosis [69, 70]. The “2-hit hypothesis” regarding 
NAFLD pathogenesis suggests that NAFLD is caused by two major factors: the accumulation of 
excessive hepatic fat and oxidative stress [6-8]. Therefore, treatment that targets one or both of 
these factors may be beneficial in combating NAFLD.  
Population studies have demonstrated that men and postmenopausal women have higher 
incidences of NAFLD which suggests the protective effects of estrogens [19, 71]. The decrease 
in estrogens due to menopause onset make postmenopausal women more susceptible to weight 
gain, fat redistribution to abdominal areas, dyslipidemia, hypertension and insulin resistance, 
which are the major hallmarks of metabolic syndrome and associated with NAFLD [72]. These 
effects, including insulin resistance and glucose homeostasis, can be reversed by estradiol (E2) 
treatment [21, 22]. Current hormone replacement therapy (HRT) typically consists of an estrogen 
or estrogen in combination with a progestin, and improve postmenopausal symptoms. However, 
there have been increased concern about the side-effects of HRTs, such as increased risk of 
breast and endometrial cancers, deep vein thrombosis and stroke. Therefore, it is essential to find 
safer alternatives to HRT that can maintain the health of non-reproductive tissues without 
stimulating reproductive tissues. In this study, we analyze the metabolic effects of a novel 
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estrogenic ligand and evaluate its potential to combat hepatic steatosis and markers of NAFLD 
caused by decreased estrogens. 
We have previously developed novel pathway preferential estrogens that modulate 
extranuclear-initiated ERα and mTOR signaling crosstalk [59]. One of these compounds, termed 
Pathway Preferential Estrogen 1 (PaPE-1), reduced ovariectomy-induced weight gain, blood 
triglyceride levels, and fat deposition, without stimulating the uterus or mammary gland, and 
displayed a pattern of metabolic tissue-selective activity that would be optimal for 
postmenopausal women by reducing fat accumulation in the body without the potential increased 
cancer risk. In the current study, we analyze the effects of PaPE-1 in the liver specifically in 
order to investigate its role in preventing hepatic lipid accumulation. To understand the 
molecular mechanism and systemic effects of PaPE-1 on metabolism in the low estrogen 
environment, we performed several genomics and postgenomics analyses in female mouse 
models. Our analyses revealed a significant role for these treatments in modulating inflammation 
and immunity-related pathways associated with the liver, as well as networks that control lipid 
deposition and circulating free fatty acid levels. Our combined liver gene expression and blood 
metabolomics analysis show that PaPE-1 is effective in normalizing fatty acid metabolism and 
inflammatory pathways associated with the liver. Our data suggest the role of PaPE-1 in 
protecting postmenopausal women from NAFLD without increasing reproductive cancer risk. 
 
3.2 MATERIAL AND METHODS 
3.2.1. Animal models and treatments.  
Studies used wildtype and Leptin mutant (ob/ob) mice in C57BL/6 background. All 
experiments involving animals were conducted in accordance with National Institutes of Health 
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standards for the use and care of animals, with protocols approved by the University of Illinois at 
Urbana-Champaign (IACUC protocol #14193). Based on our previous work on body weight 
normalization by low affinity estrogens in mice treated with controls or various estrogens, typical 
treatment differences in the weight of animals on high fat diet following ovariectomy were 5 g; 
standard deviations were approximately 3 g.  Using these predictions and a Type I error of 5% 
and a Type II error of 10%, we estimated that 8 animals were required for each group in each 
experiment [59, 61].  
Two different animal models for obesity were implemented for this study. All 
experiments were conducted in accordance with the National Institutes of Health standards for 
the use and care of animals, with protocols approved by the University of Illinois at Urbana-
Champaign. Treatment groups for both models were the same: (1) vehicle at 43% DMSO, 15% 




; (3) PaPE-1 at 300 µg/day. The first model 
used 24 female wild-type C57BL/J (Jackson Laboratory) mice housed individually in 12-h light-
dark cycle. Mice were given a high-fat diet (Harlan TD.88137), based on an AIN76a diet but 
with 45% calories from fat and 0.2% cholesterol. All mice were ovariectomized (OVX) under 
isoflurane anesthesia and treatment was administered through 60 day release osmostic minipump 
(Alzet 2006, DURECT Corporation; flow rate 0.15 µl/hr). The second model used leptin 
deficient (ob/ob) mice from a C57BL/J background. Mice were housed individually in 12-h 
light-dark cycle and given a normal AIN76a diet. Treatment was administered through 60 day 
release osmostic minipump (Alzet 2006, DURECT Corporation; flow rate 0.15 µl/hr). 40 female 
mice, C57BL/6J (RRID:IMSR_JAX:000664), from Jackson Laboratory housed individually in 




3.2.2. Food intake and body composition.  
Food intake and body weight were measured weekly for six weeks. MRIs were 
performed before treatment then at four weeks after treatment using an EchoMRI which 
measures the whole body, lean, and water mass. After six weeks of treatment, mice were 
euthanized and organs were harvested. Liver and uterus were weighed and recorded. 
 
3.2.3. RNA-seq and transcriptional profiling.  
 RNA isolated from liver was cleaned using an RNAeasy kit (Qiagen). Concentrated 
RNA was submitted to the DNA Sequencing Group at the Roy J. Carver Biotechnology Center at 
UIUC. Complementary DNA (cDNA) libraries were prepared with the mRNA TruSeq Kit 
(Illumina Inc.). Double stranded cDNA was generated from fragmented RNA and adapters were 
ligated to the ends. Casava 1.8.2. was used to base call and demultiplex samples. FASTQ files 
were trimmed using FASTQ Trimmer (version 1.0.0). TopHat (version 0.5) was used to map 
single-end RNA-seq reads to Mus musculus reference genome. Gene expression values were 
quantified from BAM files and calculated using StrandNGS (version 2.1) Quantification tool. 
Partial reads were considered and the option of detecting novel genes and exons was selected.  
Default parameters for finding novel exons and genes were specified.  DESeq normalization 
algorithm using default values was chosen. Differentially expressed genes were then determined 
by fold-change and p-value with Benjamini and Hochberg multiple test correction for each gene 
for each treatment relative to the vehicle control. We considered genes with fold-change >2 and 
FDR (or q) < 0.05 as = significantly, differentially expressed.  
 
3.2.4. Real-time RT-qPCR. 
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Liver tissue from each animal (8 animals/treatment group) or HepG2 cells were 
homogenized in 1 mL of TRIzol reagent, and total RNA was isolated. RNA was transcribed into 
cDNA using M-MuLV Reverse Transcriptase (BioLabs). Fast Start Universal SYBR Green 
reagent [56] and an Applied Biosystem Step One Plus qPCR system were used for the RT-qPCR 
reaction. Results were normalized to 36B4, and the relative difference in gene expression from 
the vehicle was calculated using the ∆∆Ct method. PCR primer sequences were obtained from 
PrimerBank (https://pga.mgh.harvard.edu/primerbank/) 
 
3.2.5. Metabolic profiling. 
About 500 µl of blood was collected from abdominal aorta. Blood collected at the end of 
the experiment was mixed with 10 µl of 0.5 M EDTA and centrifuged for 10 min at 1,000 x g to 
isolate the plasma. Plasma samples from each animal were collected and stored at -80ºC until 
submitted to the Metabolomics Center in the Roy J Carver Biotechnology Center (CBC) at 
UIUC. GC/MS whole metabolite profiling was performed to detect and quantify the metabolites 
by using Gas chromatography-mass spectrometry (GC/MS) analysis. Metabolites were extracted 
from 50 µl of plasma according to Agilent Inc. application notes. The hentriacontanoic acid was 
added to each sample as the internal standard prior to derivatization. Metabolite profiles were 
acquired using an Agilent GC-MS system (Agilent 7890 gas chromatograph, an Agilent 5975 
MSD, and an HP 7683B autosampler). The spectra of all chromatogram peaks were evaluated 
using the AMDIS 2.71 and a custom-built database with 460 unique metabolites. All known 
artificial peaks were identified and removed prior data mining. To allow comparison between 
samples, all data were normalized to the internal standard in each chromatogram. This analysis 
identifies about 150 plasma metabolites and reports a relative abundance of metabolites, which 
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enables us to compare same metabolites across the sample batch.  Metabolomic data were 
analysed using Pathway Analysis modules in Metaboanalyst 3.0 [73].  
 
3.2.6. Liver Histology. 
Liver tissue sections were embedded in Tissue-Tek O.C.T. compound and frozen. 
Sections were fixed in 10% NBF then stained with hematoxylin and eosin (H&E) or Oil Red O. 
Images were quantified using Fiji software. 
 
3.2.7. Cell Culture and Treatments. 
ERα+ HepG2 cells, liver cells from a hepatoma in a 12-year old boy, were obtained from 
and grown as recommended by the American Type Culture Collection. Cells were maintained in 
William’s medium with non-essential amino acid salts (NEAA), supplemented with 5% calf 
plasma (HyClone), 100100µg/mL penicillin/streptomycin (Invitrogen), and sodium bicarbonate. 
Cells were grown for at least 5 days in this media prior to use.  
 
3.2.8. Neutral Lipid Droplet Staining 
HepG2 cells seeded in 96-well plates were fixed with 4% formaldehyde in PBS. After 
fixation, cells were washed with PBS and stained using Invitrogen’s HCS LipidTox Neutral 
Green Lipid Stain for cellular imaging. Cells were counterstained with DAPI and viewed via 






3.2.9. Statistical Analysis 
Data from gene expression and animal studies were analyzed using either one-way 
analysis of variance (ANOVA) model to compare different ligand effects, or two-way-ANOVA 
to compare time-dependent changes. Statistical significance was established at α = 0.05. All data 
was normally distributed unless otherwise noted. Normally distributed data was analyzed using 
pairwise t tests with a Bonferroni correction to identify treatments that were significantly 
different from each other (*P < 0.05, **P < 0.01, ****P <0.0001). For every main effect that was 
statistically significant at α=0.05, pairwise t-tests were conducted to determine which ligand or 
inhibitor treatment levels were significantly different from each other. For these t-tests, the 
Bonferroni correction was employed to control experiment wise type I error rate at α=0.05 
followed by Bonferroni post hoc test. Data that were not normally distributed were analyzed 
using Mann Whitney test for nonparametric data (*P < 0.05, **P < 0.01, ****P <0.0001). 
Statistical significance was calculated using GraphPad Prism for Windows (GraphPad Software, 




3.3.1. PaPE-1 is effective in decreasing ovariectomy-associated weight gain and hepatic lipid 
deposition without stimulating reproductive tissue. 
Body weight of wild-type high fat fed or diet induced obesity (DIO) mice were 
significantly lowered by E2 and PaPE-1 after 6 weeks of treatment as have been previously 
reported (Fig 3.1A). In ob/ob mice, PaPE-1 did not significantly change body weight compared 
to the control, whereas E2 treatment increased body weight. The increase in body weight in E2 
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treated animals was not attributed to fat mass as shown by MRI but rather the water and lean 
mass of the animals. MRI analysis of animals showed that E2 and PaPE-1 significantly 
decreased fat mass in DIO mice whereas only E2 decreased fat mass in ob/ob mice (Fig 3.1B). 
At harvest after 6 weeks of treatment, liver weight of PaPE-1 animals were significantly lower 
than vehicle in both DIO mice and ob/ob models (Fig 3.1C). Furthermore, PaPE-1 treatment, 
unlike E2 treatment, did not increase uterine weight in both models (Fig 3.1D). Statistical 
significance was established at α = 0.05. All weights were normally distributed. Pairwise t tests 
with a Bonferroni correction were used to identify treatments that were significantly different 
from each other (*P < 0.05, **P < 0.01, ***P <0.001, ****P <0.0001). 
In order to correlate hepatic lipid accumulation with the differences in liver weights, 
histology was performed. H&E and Oil Red O staining of liver tissue (Fig 3.2A.) highlighted the 
estrogenic effects of PaPE-1 treatments on hepatic tissue. PaPE-1 and E2 treated animals had 
significant reduction in hepatic steatosis compared to vehicle treated animals. The decreased 
steatosis visualized by liver staining correlated with the decreased liver weights in these animals 
suggesting that the decreased liver weights are due to decreased steatosis and lipid deposition. 
Quantification of lipid droplet size based on Oil Red O staining confirmed a significant decrease 
in droplet size in both estrogenic treatments (Fig 3.2B). We verified the effects of PaPE-1 and E2 
in human hepatocyte HepG2 cells by treating with V, E2, and PaPE-1 with and without Lipid 
Mixture 1 (LM) from Sigma-Aldrich. Then we visualized the lipid accumulation using 
fluorescent LipidTox Neutral Green Lipid Stain (Fig 3.2C). Quantification (Fig 3.2D) was done 
using Fiji software. E2 and PaPE-1 were both effective in reducing lipid accumulation in HepG2 




3.3.2. PaPE-1 modulates gene expression to decrease lipid accumulation in the liver. 
To understand change in gene expression programs induced by PaPE-1, RNA was 
extracted from mouse liver and RNA-seq was performed. Regulated genes are considered to be 
those with expression fold change >2 at p-value < 0.05 (n=3 biological replicates). Based on 
transcriptional profiling of these treatments, PaPE-1 up-regulates and down-regulates common as 
well as distinct groups of genes compared to E2 (Fig 3.3A). qPCR validation of selected genes 
Fasn and Srebp1c correlate to RNA-seq data (Fig 3.3B). PaPE-1 significantly decreases Fasn and 
Srebp1c gene expression in WT HFD mice. In ob/ob mice, PaPE-1 does not significantly 
decrease Fasn and Srebp1c gene expression, but the trend is still present. To confirm this in 
hepatocyte cells, HepG2 cells were treated with V, E2, and PaPE-1 in the presence of LM and 
qPCR was performed. (Fig 3.3C). FASN and SREBP1c expression were both significantly 
decreased in HepG2 cells and correspond to mouse model data. 
Volcano plots of gene expression data show several genes significantly affected by PaPE-1 
treatment, which differ from E2 treatment (Fig 3.3D). Statistical significantly was determined at 
α=0.05. Each row was analyzed individually, without assuming a consistent standard deviation.  
 
3.3.3. Metabolomics and integrated pathway analysis show PaPE-1 reduces inflammation in the 
liver. 
To understand changes in the composition of blood metabolites induced by various 
estrogens we obtained plasma from animals at the time of harvest and performed whole 
metabolomics analysis at the Metabolomics Center, Roy J. Carver Biotechnology Center at 
UIUC. Volcano plots of metabolomics data show several metabolites significantly affected by 
PaPE-1 treatment, which differ from those affected by E2 treatment (Fig 3.4A). Reduced 
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glutathione was significantly decreased in DIO mice but not ob/ob mice. Several fatty acids were 
also significantly decreased in both mouse models. PaPE-1 impacted several metabolites distinct 
and in several common to E2 (Fig 3.4B). Additionally, there were a few metabolites that were 
regulated similarly in the two mouse models (Fig 3.4C). 
Integrated pathway analysis was conducted using gene expression and metabolite 
composition data in Metaboanalyst 3.0 (Fig 3.5A). Retinol Metabolism was significantly 
affected by PaPE-1 treatment in both DIO (p-value = 0.003054) and ob/ob (p-value = 8.78e-5). 
Drug metabolism-cytochrome p450 was also significantly affected by PaPE-1 treatment in both 
DIO (p-value = 0.023279) and ob/ob (p-value = 0.001582). Glutathione metabolism was 
significantly modulated by PaPE-1 treatment in DIO (p-value = 0.000915) mice and a similar 
trend was shown in ob/ob mice (p-value = 0.065448). Lastly, Linoleic acid metabolism was 
significantly modulated in ob/ob mice (p-value = 0.026451) and a similar trend was shown in 
DIO mice (p-value 0.083757).  
Several genes and metabolites correlated with the glutathione metabolism pathway in 
DIO and ob/ob mouse models including Gsta1, which is significantly regulated in both DIO and 
ob/ob mouse models (Figure 3.5B). Integrated GO term analysis was performed using genes and 
metabolites significantly affected by PaPE-1 treatment. GO terms that are decreased by PaPE-1 
treatment are highlighted in blue whereas GO terms that are increased are highlighted in red. In 
the DIO model, terms including cellular response to oxidative stress and cholesterol biosynthetic 
process were shown to be decreased by PaPE-1 treatment (Figure 3.5C). In the ob/ob model, 
terms including cell cycle regulation are decreased whereas cellular oxidant detoxification is 
increased (Figure 3.5D). Therefore, PaPE-1 targets certain inflammation and lipid metabolic 






In the present study, we characterize the effects of PaPE-1 using gene expression, 
metabolite levels, and liver histology. Replacement of estrogens after ovariectomy overall 
improved weight gain, body fat deposition, plasma metabolite composition, and liver gene 
expression associated with lipid metabolism and inflammation. PaPE-1 also improved liver gene 
expression and plasma metabolite composition in severely obese ob/ob leptin deficient mice. In 
particular, integrated pathway analysis showed that Retinol Metabolism, Glutathione 
Metabolism, and Linoleic Acid Metabolism were modulated by PaPE-1 treatment.  
The prevalence of metabolic syndrome among women is increasing, although there is no 
such significant trend for men [74]. Metabolic syndrome is strongly associated with NAFLD and 
liver steatosis. Furthermore, estrogens have a protective effect against NAFLD and have been 
shown to reverse steatosis in both male and female models [19, 75, 76]. Lipid accumulation in 
the liver in the form of large cytosolic lipid droplets has been considered a factor in the “first hit” 
of the development of NAFLD [17]. In our previous studies, PaPE-1 was shown to have a major 
impact on fat depot of animals, where PaPE-1 decreased the weight of all fat depots including 
perigonadal, perirenal, and subcutaneous adipose tissues [59]. Additionally, PaPE-1 does not 
increase the uterus weight in ovariectomized animals. Our current results correlate with this 
previous data in that we see decreased fat depots in DIO mice. Liver weights and hepatic lipid 
droplet size are decreased not only in DIO mice but also in ob/ob mice, showing PaPE-1’s 
protective effects against the “first hit” in the development of NAFLD. 
In addition to targeting factors in the “first hit” of NAFLD development, PaPE-1 
modulates several metabolic pathways associated to reducing fibrogenesis and inflammation. 
One of these pathways is Glutathione Metabolism. Glutathione is a major antioxidant that 
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prevents oxidative stress in the liver by quenching ROS. Human GSTs are family of enzymes 
capable of detoxifying electrophilic molecules generated through oxidative stress [77]. PaPE-1 
treatment in ovariectomized mice given a HFD significantly decreased the levels of several 
enzymes in the glutathione pathway including Gsta1. Glutathione transferase (GST) isoforms 
and their correlating mRNA levels in particular have increased levels in NAFLD progression 
[78]. Therefore, PaPE-1 treated animals may have less ROS generation and inflammation.  
Though PaPE-1 affected similar metabolic pathways, not all genes and metabolites were 
significantly correlated in both DIO and ob/ob mouse models. This could be due to the 
differences in gene expression and signaling in ob/ob mice. Previous studies have shown that 
though ob/ob mice develop steatosis, they are less prone to develop steatohepatitis and fibrosis 
compared to other mouse models such as in DIO mice [79-81]. These differences have been 
attributed to the characterization of leptin as an essential mediator of hepatic fibrogenesis [79, 
80].   
Our results show that PaPE-1 showed significant changes in inflammation and lipid 
metabolic pathways in two different mouse models that simulate metabolic dysfunction due to 
loss of estrogen cycling. Based on the “two-hit hypothesis”, NAFLD is best treated by targeting 
both inflammation and lipid accumulation in the liver. It appears that PaPE-1 modulates 
pathways in both factors of the “two-hit hypothesis” suggesting a protective effect against 
steatosis and NAFLD. Overall, our data suggest the role of PaPE-1 in protecting against liver 
steatosis and inflammation that could be caused by loss of estrogens. PaPE-1 provides a 
metabolic benefit while preventing reproductive tissue stimulation. This study shows a promising 





BAZEDOXIFENE AND CONJUGATED ESTROGEN COMBINATION MAINTAINS 
METABOLIC HOMEOSTASIS AND BENEFITS LIVER HEALTH 
4.1 INTRODUCTION 
With increased life expectancy, a significant portion of the US population will quickly be 
over 60, a majority of which will be women [82]. Estrogen deficiency in postmenopausal women 
can lead to higher incidences of cardiovascular disease and skeletal degeneration, as well as, 
obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) [72, 83, 84]. These 
effects, including insulin resistance and glucose homeostasis, can be reversed by estradiol (E2) 
treatment [21, 22]. Current hormone replacement therapy (HRT) typically consists of an estrogen 
or estrogen in combination with a progestin, and improve postmenopausal symptoms. However, 
there have been increased concern about the side-effects of HRTs, such as increased risk of 
breast and endometrial cancers, deep vein thrombosis and stroke.  
Selective estrogen receptor modulators (SERMs) are compounds that can bind to 
estrogen receptors (ER) and can exert agonistic or antagonistic activity. Bazedoxifene (BZA) is 
one such SERM that has estrogen agonist activity in bone and reduces osteoporosis while 
possibly having antagonistic activity in the breast and uterus [85, 86]. In mice, the antagonistic 
effects of BZA in the mammary gland can block E2 and inhibit the growth of tamoxifen sensitive 
and resistant tumors [87]. In cell culture models conjugated estrogen (CE) was much less potent 
in inducing breast cancer cell proliferation, and BZA entirely suppressed this effect [88].  
Although classic HRT uses an estrogen and progestin in combination, replacing progestin with 
SERMs could more effectively prevent side-effects. This new combination of estrogen and 
SERM has been described as the tissue-selective estrogen complexes (TSECs). Most notably, the 
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TSEC comprised of CE and BZA has been shown to prevent osteoporosis with minimal effects 
on reproductive organs [89-91]. This combination was approved by the FDA for the prevention 
of postmenopausal osteoporosis and the treatment of moderate-to-severe vasomotor symptoms 
caused by menopause. Recently, the possibility of this TSEC in preventing metabolic disorders is 
beginning to be explored. It has been shown that the TSECs prevent visceral adiposity and had a 
significant impact on body weight increase compared to control in ovariectomized mice [92, 93]. 
CE+BZA had a significant decrease in both uterine and mesenteric white adipose tissue (WAT) 
though it did not cause an increase in uterine weight, which CE only and E2 treatments did [93]. 
TSEC decreases serum leptin levels, leptin/adiponectin ratio, and levels of thiobarbituric acid 
reactive substances (TBARS) compared to control mice suggesting normalization of serum 
adipokines and systemic inflammation [92]. Furthermore, the TSEC decreased hepatic fatty acid 
synthase (FAS) enzymatic activity [92] and significant decreases in liver lipid deposition [93] 
suggesting benefits to liver health.  
To understand the molecular mechanism and systemic effects of CE+BZA combination 
on metabolism in the low estrogen environment, we performed transcriptomics and 
metabolomics analysis in ovariectomized female mice.  Our analysis revealed a significant role 
for CE+BZA combination in modulating inflammation and immunity-related pathways and 
decreasing expression of gene networks that control lipid deposition and circulating free fatty 
acid levels in the liver. Our results are consistent with decreased blood free fatty acid and 
cholesterol levels as evidenced by plasma metabolomics analysis.  In summary, our combined 
liver gene expression and blood metabolite analysis showed that CE+BZA combination is very 
effective in mitigating weight gain due to loss of estrogens, and normalizes fatty acid metabolism 




4.2 MATERIAL AND METHODS 
4.2.1. Animal model and treatments.  
40 female mice, C57BL/6J (RRID:IMSR_JAX:000664), from Jackson Laboratory housed 
individually in 12-h light-dark cycle. At 8 weeks of age, mice were given a high-fat diet (Harlan 
TD.88137), which is based on an AIN76a diet but with 45% of calories from fat and 0.2% 
cholesterol. They were given water ad libitum. Based on our previous work on body weight 
normalization by low affinity estrogens in mice treated with controls or various estrogens, typical 
treatment differences in the weight of animals on high fat diet following ovariectomy were 5 g; 
standard deviations were approximately 3 g.  Using these predictions and a Type I error of 5% 
and a Type II error of 10%, we estimated that 8 animals were required for each group in each 
experiment [94, 95]. All mice were ovariectomized (OVX) under isoflurane anaesthesia at ten 
weeks of age and were divided randomly into five treatment groups (8 animals per treatment 













; (5) CE+BZA. Conjugated estrogens were 
centrifuged at 9,000g for 1 minute to remove insoluble cellulose before loading into a 60-day 
release osmotic minipump (Alzet 2006, DURECT Corporation; flow rate 0.15 µl/hr. All 
experiments involving animals were conducted with protocols approved by the University of 
Illinois at Urbana-Champaign and by the National Institutes of Health standards for use and care 
of animals (IACUC Protocol 14193).  
 
4.2.2. Food intake and body composition.  
Daily food intake was monitored. Food intake and body weight were measured weekly for six 
weeks. MRIs were performed before treatment then at four weeks after treatment using an 
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EchoMRI which measures the whole body, lean, and water mass. After six weeks of treatment, 
mice were euthanized and organs were harvested. Perigonadal white adipose tissue (WAT),  
mesenteric adipose tissue (MAT), kidney adipose tissue (KAT), subcutaneous adipose tissue 
(SAT), liver, and uterus were weighed.  
 
3.2.6. Liver Histology. 
Liver tissue sections were embedded in Tissue-Tek O.C.T. compound and frozen. 
Sections were fixed in 10% NBF then stained with hematoxylin and eosin (H&E) or Oil Red O. 
Images were quantified using Fiji software. 
 
4.2.3. Real-time RT-qPCR. 
 Liver tissue from each animal (8 animals/treatment group) was homogenized in 1 mL of TRIzol 
reagent, and total RNA was isolated. RNA was transcribed into cDNA using M-MuLV Reverse 
Transcriptase (BioLabs). Fast Start Universal SYBR Green reagent (Roche) and an Applied 
Biosystem Step One Plus qPCR system were used for the RT-qPCR reaction. Results were 
normalized to 36B4, and the relative difference in gene expression from the vehicle was 
calculated using the ∆∆Ct method. PCR primer sequences were obtained from PrimerBank 
(https://pga.mgh.harvard.edu/primerbank/) 
 
4.2.4. RNA-seq and transcriptional profiling.  
RNA isolated from liver using the same method as above was cleaned using an RNAeasy kit 
(Qiagen). Concentrated RNA was submitted to the DNA Sequencing Group at the Roy J. Carver 
Biotechnology Center at UIUC. Complementary DNA (cDNA) libraries were prepared with the 
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mRNA TruSeq Kit (Illumina Inc.). Double stranded cDNA was generated from fragmented RNA 
and adapters were ligated to the ends. Casava 1.8.2. was used to base call and demultiplex 
samples. FASTQ files were trimmed using FASTQ Trimmer (version 1.0.0). TopHat (version 
0.5) was used to map single-end RNA-seq reads to Mus musculus reference genome. Gene 
expression values were quantified from BAM files were calculated using StrandNGS (version 
2.1) Quantification tool. Partial reads were considered and the option of detecting novel genes 
and exons was selected.  Default parameters for finding novel exons and genes were specified.  
DESeq normalization algorithm using default values was chosen. Differentially expressed genes 
were then determined by fold-change and p-value with Benjamini and Hochberg multiple test 
correction for each gene for each treatment relative to the vehicle control. We considered genes 
with fold-change >2 and FDR (or q) < 0.05 as = significantly, differentially expressed.  
 
4.2.5. Metabolic profiling. 
500 ul of whole blood was extracted from abdominal aorta at the time of tissue harvest. 10 µl of 
0.5 M EDTA was added to blood samples and samples were centrifuged for 10 min at 1,000 x g 
to isolate the plasma. Plasma samples from each animal were submitted to the Metabolomics 
Center in the Roy J Carver Biotechnology Center (CBC) at UIUC.  GC/MS whole metabolite 
profiling was performed to detect and quantify the metabolites by using Gas chromatography-
mass spectrometry (GC/MS) analysis. Metabolites were extracted from 50 µl of plasma 
according to Agilent Inc. application notes. The hentriacontanoic acid was added to each sample 
as the internal standard prior to derivatization. Metabolite profiles were acquired using an 
Agilent GC-MS system (Agilent 7890 gas chromatograph, an Agilent 5975 MSD, and an HP 
7683B autosampler). The spectra of all chromatogram peaks were evaluated using the AMDIS 
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2.71 and a custom-built database with 460 unique metabolites. All known artificial peaks were 
identified and removed prior data mining. To allow comparison between samples, all data were 
normalized to the internal standard in each chromatogram. This analysis identifies about 150 
plasma metabolites and reports a relative abundance of metabolites, which enables us to compare 
same metabolites across the sample batch. Metabolomic data was integrated with gene 
expression data and analysed by Pathway Analysis modules in Cytoscape using the ClueGo 
application.  
 
4.2.6. Statistical Analyses. 
Data from gene expression and animal studies were analysed using either a one-way analysis of 
variance (ANOVA) model to compare different ligand effects, a two-way-ANOVA model to 
compare time-dependent changes. All data was normally distributed unless otherwise noted. 
Normally distributed data was analyzed using pairwise t tests with a Bonferroni correction to 
identify treatments that were significantly different from each other (*P < 0.05, **P < 0.01, 
****P <0.0001). For every main effect that was statistically significant at α=0.05, pairwise t-
tests were conducted to determine which ligand or inhibitor treatment levels were significantly 
different from each other. For these t-tests, the Bonferroni correction was employed to control 
experiment wise type I error rate at α=0.05 followed by Bonferroni post hoc test. Data that were 
not normally distributed were analyzed using Mann Whitney test for nonparametric data (*P < 
0.05, **P < 0.01, ****P <0.0001). Statistical significance was calculated using GraphPad Prism 
for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). Mean and 




4.2.7. Availability of Data and Materials. 
Gene expression data is submitted to GEO database under the number GSE92968 and going to 




4.3.1. CE+BZA is very effective in decreasing ovariectomy-associated weight gain and lipid 
deposition without stimulating reproductive tissue.  
To characterize the effectiveness of various estrogens on normalizing weight gain after 
ovariectomy, we monitored body weight (Fig 4.1A) weekly. A one-way ANOVA model was 
fitted to assess the conditions of ligand treatment on body weight, fat mass, liver, uterine and 
various adipose depot weights (Fig 4.1). Statistical significance was established at α = 0.05. All 
weights were normally distributed (name of the test). Pairwise t tests with a Bonferroni 
correction were used to identify treatments that were significantly different from each other (*P 
< 0.05, **P < 0.01, ***P <0.001, ****P <0.0001).  Total body weight of ovariectomized mice 
fed a high fat diet was significantly decreased in E2, CE only, and CE+BZA groups compared to 
the control. CE+BZA showed the greatest effect on preventing ovariectomy-induced weight gain 
(P < 0.001).  
MRI analysis of fat mass at four weeks of treatment indicated that all treatment groups 
had fat mass significantly lower than the control (Fig 4.1B). Only CE and CE+BZA was 
comparable to E2 in terms of effectiveness (P < 0.001). At harvest after six weeks of treatment, 
liver and uterus were removed and weighed. Uterus weight comparison between treatments 
showed that E2 and CE had weights significantly higher than control and the BZA and CE+BZA 
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were no different from the control (Fig 4.1C). All treatment groups had lower liver weight 
suggesting an improvement in hepatic steatosis (Fig 4.1D). CE+BZA had the lowest liver weight 
compared to the control (P < 0.001, Fig 4.1D). Therefore, we see that CE+BZA lowers liver and 
fat mass without increasing uterus weight like E2 and CE. These data suggests an additive effect 
of CE+BZA treatment on whole body and organ weights. 
Since we observed a statistically significant decrease in liver weight, H&E and Oil Red O 
staining was performed on liver tissue to assess hepatic lipid accumulation (Fig 4.2A). All 
treatments appeared to decrease hepatic lipid accumulation and reduce lipid droplet size based on 
H&E and Oil Red O staining (Fig 4.2A). Lipid droplet size was calculated using Fiji software 
(Fig 4.2B). CE+BZA was very effective in preventing steatosis in ovariectomized animals that 
were fed a high fat diet.  
 
4.3.2. CE+BZA treatment regulates common and unique groups of genes in mice liver.  
To understand changes in gene expression programs induced by CE+BZA, RNA was 
extracted from mouse liver and RNA-seq was performed. Regulated genes are considered to be 
those with expression fold change >2 at p-val < 0.05. Based on the transcriptional profiling of 
liver from animals that received different treatments (Fig 4.3A), CE+BZA up-regulates and 
down-regulates common as well as distinct groups of genes compared to E2, CE, and BZA (Fig 
4.3B). Regarding upregulated genes, CE+BZA shares the most similar modulation with BZA. 
However, in terms of downregulated genes, CE+BZA shares the most similar modulation with 
E2.  
We validated several of the genes that we identified from this analysis, including Cfd and 
Pparɣ (Fig 4.3C), which matched the patterns of expression. Compared to individual treatments 
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CE or BZA, CE+BZA was not significantly different in Pparɣ expression. However, CE+BZA 
had the most significant decrease in Pparɣ expression compared to vehicle. CE+BZA treatment 
is significantly different in Cfd expression compared to CE only but not to BZA. Overall, it 
appears that the effects of the combination of CE+BZA on gene regulation is likely additive 
rather than synergistic.  
Volcano plots of gene expression data show several genes significantly affected by 
CE+BZA treatment which differ from E2 treatment (Fig 4.3C). Statistical significance was 
determined at α=0.05 and greater than a 2-fold change. Each treatment was analysed 
individually, without assuming a consistent standard deviation. 
 
4.3.4. CE+BZA treatment distinctly alters blood metabolite composition. 
To understand changes in the composition of blood metabolites induced by various 
estrogens, we obtained plasma from animals at the time of harvest and performed whole 
metabolomics analysis at the Metabolomics Center, Roy J. Carver Biotechnology Center at 
UIUC. Based on metabolomics profiling of these treatments (Fig 4.4A), downregulated and 
upregulated metabolites were identified (Fig 4.4B). Our analysis identified several common and 
distinct metabolites between E2 and CE+BZA treatment (Fig 4.4C). Among them, 4 metabolites 
were significantly regulated by CE+BZA treatment (Fig 4.4D). 
In a second analysis, we integrated these data with our gene expression analysis from Fig 
4.3. Significantly affected genes and metabolites were integrated using Cytoscape. 
Downregulated GO terms related to fat digestion, fatty acid metabolism, and cholesterol 
metabolism are shown. Additionally, upregulated GO terms related to cell cycle, cell signalling, 
and cell differentiation were also shown. In particular, Cel, Pnpla3, and Lep are associated with 
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downregulated lipid and cholesterol biosynthetic pathways.  Coprostan-3-ol, a biproduct of 
cholesterol metabolism, is significantly increased in blood plasma with CE+BZA treatment. 
Therefore it seems that there are several genes and metabolites related to lipid and cholesterol 
metabolism that are affected by CE+BZA treatment. 
Integrated pathway analysis also showed modulation of immune responses. Over 100 
genes associated with the GO term cellular response to oxygen-containing compound were found 
to be overexpressed in CE+BZA treatment. Furthermore, hypotaurine was significantly increased 
in CE+BZA treated animals. Hypotaurine supplementation has been shown to decrease oxidative 
stress and fibrosis [96]. Hypotaurine can also prevent steatohepatitis and hepatic lipid 
accumulation [96]. Therefore, CE+BZA treatment affects pathways that can protect against 
oxidative damage which may slow NAFLD to NASH progression. 
 
4.4. DISCUSSION 
In the present study, we characterize the potential for conjugated estrogens and 
bazedoxifene combination treatment in preventing ovariectomy induced weight gain and hepatic 
lipid accumulation. Replacement of estrogens after ovariectomy overall improved weight gain, 
body fat deposition, and liver gene expression associated with lipid metabolism and 
inflammation, plasma metabolite composition.  
Our data also showed significant changes in liver transcriptome after estrogen 
replacement (particularly with CE+BZA). Cfd (Complement factor D) has been shown the 
promote adipogenesis and knockdown of Cfd resulted in inhibited lipid accumulation [97]. Pparɣ 
regulates lipogenesis and may also be stimulated by Cfd [97, 98]. In high fat fed mice, Pparɣ 
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expression is increased, leading to liver steatosis [99]. CE+BZA appears to counter this effect in 
our dataset.  
Our integrative analysis identified CE+BZA target genes important for liver physiology. 
Cel is gene linked to carboxyl ester lipase, previously named cholesterol esterase, which is an 
enzyme that hydrolyses cholesterol esters, acylglycerols, and phospholipids [100]. Carboxyl 
ester lipase can be directly secreted by hepatocytes and is suggested to play a role in hepatic 
secretion-capture pathways of lipoproteins [101, 102]. A decrease in Cel expression has been 
shown to inhibit lipid uptake in the liver [103]. Pnpla3 (adiponutrin) is upregulated in 
intracellular lipid accumulation [104]. Pnpla3 overexpression causes larger lipid drop formation 
and increased lipid accumulation leading to a NAFLD phenotype in mice [104]. Additionally 
Lep (leptin) expression is decreased, which encodes an adipokine that is upregulated in obese 
individuals. Leptin regulates satiety and was found to be overexpressed in patients with NASH 
[105]. Increased leptin can induce insulin resistance and elevated fatty acid levels leading to lipid 
peroxidation in the liver promoting steatosis [106]. All three of Cel, Pnpla3, and Lep are 
significantly downregulated in CE+BZA treatment and suggests a decrease in lipid metabolism 
and storage pathways. Metabolites tetradecanoic acid and coprostan-3-ol are also related to lipid 
and cholesterol biosynthetic pathways. Tetradecanoic acid or myristic acid is a fatty acid that is 
elevated in NAFLD [107]. Tetradecanoic acid is significantly decreased with CE+BZA 
treatment. Coprostan-3-ol is a cholesterol derivative poorly absorbed by the human intestine that 
is inversely associated with cholesterol levels in the liver [108]. 
NAFLD progression is suggested to be caused by two major factors: the accumulation of 
excessive hepatic fat and oxidative stress or inflammation [6-8]. These factors contribute to the 
“2-hit hypothesis” regarding NAFLD pathogenesis. Based on this hypothesis, NAFLD is best 
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treated by targeting both “hits”. Based on our analysis using significant metabolite and gene 
expression data, several genes and metabolites associated with lipid and cholesterol metabolic 
pathways are downregulated, suggesting lower lipid and cholesterol accumulation in the liver. 
Additionally, pathways associated with protection against oxidative damages are improved with 
CE+BZA treatment. By modulating pathways associated with lipid and cholesterol accumulation 
and inflammation, CE+BZA targets both “hits” of NAFLD pathogenesis and may effectively 
prevent symptoms leading to NAFLD and NASH. 
Overall, our data suggest a major role for various estrogen in affecting metabolic tissues 
including liver and fat depots and changing plasma metabolite levels. CE+BZA appears to have 
protective effects against disease progression of certain metabolic diseases such as obesity and 
NAFLD. Using the right combination of these estrogens, as in the case of CE+BZA, improves 
metabolic benefit while preventing stimulation of reproductive tissues and offer a safer solution 






POTENTIAL MECHANISMS OF ESTROGEN AND MICROBIOME CROSSTALK 
5.1 INTRODUCTION 
In postmenopausal women, hormone replacement therapy (HRT) improves 
postmenopausal symptoms such as weight gain, osteoporosis risk, dyslipidemia, and insulin 
resistance [21, 22]. Many of these symptoms lead to increased metabolic syndrome risk. 
However, relative estrogen excess can contribute to hormone-driven breast cancer [109, 110]. 
The ratio of estrogen metabolites to parent estrogens has also been linked to postmenopausal 
cancer risk which increased with higher circulating concentrations of parent estrogens estradiol 
and estrone [111]. Conjugated estrogen and bazedoxifene combination is a current hormone 
replacement therapy that has great potential for improving metabolic health without increasing 
cancer risk. In cell culture models conjugated estrogen (CE) was much less potent in inducing 
breast cancer cell proliferation, and BZA entirely suppressed this effect [88].CE+BZA decreases 
both uterine and mesenteric white adipose tissue (WAT) weight without increasing uterine 
weight [93]. This combination also decreases serum leptin levels, leptin/adiponectin ratio, and 
levels of thiobarbituric acid reactive substances (TBARS) compared to control mice suggesting 
normalization of serum adipokines and systemic inflammation [92]. The effects of this 
combination on metabolism have been documented, however the effects on the microbiome have 
not. 
Recent evidence suggests there is estrogen and microbiome crosstalk. Estrogen-like 
compounds, when consumed, may promote the proliferation and growth of certain types of 
bacteria. Soy isoflavones such as daidzein, genistein, and glycitin can significantly alter fecal 
bacterial community structure and composition in postmenopausal women by increasing the 
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concentration of the beneficial gram-positive Bifidobacterium while suppressing Clostridiaceae, 
which can be the cause of several human diseases [57, 58]. Some bacteria also metabolize certain 
estrogen-like compounds or phytoestrogens like soy isoflavone to produce more biologically 
active forms that have high affinity for human ERs. More recently, intestinal microbiota genes 
that are capable of producing estrogen metabolizing enzymes have been identified. This set of 
genes, or the “estrobolome”, implies a potential for biomarker applications in several metabolic 
diseases [112]. Estrogens may be conjugated by the liver through glucuronidation or sulfation in 
order to be excreted by the body [113]. Bacterial species in the gut may deconjugate these 
estrogens in the gut and cause estrogens to be reabsorbed into circulation [114]. Collectively 
these data suggest gut microbiota as a potential biomarker for evaluating and preventing 
estrogen-associated pathologies. To understand the interaction between estrogens and the 
microbiome, we performed genomics and postgenomics analysis in a female mouse model. 
Additionally, we explored the enzyme activity of certain bacteria on metabolized estrogens. 
 
5.2 MATERIAL AND METHODS 
5.2.1. Animal model and treatments.  
40 female mice, C57BL/6J (RRID:IMSR_JAX:000664), from Jackson Laboratory 
housed individually in 12-h light-dark cycle. At 8 weeks of age, mice were given a high-fat diet 
(Harlan TD.88137), which is based on an AIN76a diet but with 45% of calories from fat and 
0.2% cholesterol. They were given water ad libitum. Based on our previous work on body weight 
normalization by low affinity estrogens in mice treated with controls or various estrogens, typical 
treatment differences in the weight of animals on high fat diet following ovariectomy were 5 g; 
standard deviations were approximately 3 g.  Using these predictions and a Type I error of 5% 
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and a Type II error of 10%, we estimated that 8 animals were required for each group in each 
experiment [94, 95]. All mice were ovariectomized (OVX) under isoflurane anaesthesia at ten 
weeks of age and were divided randomly into five treatment groups (8 animals per treatment 













; (5) CE+BZA. Conjugated estrogens were 
centrifuged at 9,000g for 1 minute to remove insoluble cellulose before loading into a 60-day 
release osmotic minipump (Alzet 2006, DURECT Corporation; flow rate 0.15 µl/hr. All 
experiments involving animals were conducted with protocols approved by the University of 
Illinois at Urbana-Champaign and by the National Institutes of Health standards for use and care 
of animals (IACUC Protocol 14193).  
 
5.2.2. Microbial DNA Extraction.  
Fecal and cecal samples collected at the time of harvest contents using QIAmp DNA 
stool Mini Kit (Qiagen, CA) with bead-beating [115, 116]. DNA concentration and 
quality was measured using Cytation5 (Biotek). The 16S rRNA sequencing was performed by 
the DNA Sequencing Group at the Roy J. Carver Biotechnology Center at UIUC. The V3-V5 
variable regions of the 16S rDNA were amplified using primers (forward F357: 5’-
CCTACGGGAGGCAGCAG-3’ and reverse R926: 5’-CCGTCAATTCMTTTRAGT-3’). The 
quality of the PCR products was analysed using an Agilent 2100 BioAnalyzer. 
Paired-end reads were generated with the Illumina® MiSeq platform for each sample, at 
a read length of 250 nucleotides. The reads were demultiplexed and quality-filtered using 
Trimmomatic (version 0.30) with a Phred score cut-off of 33 [117]. Data analysis was performed 
through the QIIME pipeline (version 1.9.0). Operational taxonomical unit (OTU)-picking was 
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performed by searching the Greengenes 16S rRNA gene database 
(http://greengenes.secondgenome.com/downloads). Prior to analysis of the 16S amplicon 
sequencing data, rarefaction was used to standardize the number of sequences per sample, thus 
facilitating comparisons among groups. Principal Coordinates Analysis (PCoA) was performed 
on all of the groups based on unweighted Unifrac tables. 
 
5.2.3. Extended Random Forest. 
Extended Random Forest was applied to identify and rank OTUs predictive of the percent 
weight gain. This process uses the Random Forest (RF) algorithm followed by stability analysis 
and feature permutation to determine all relevant OTUs. RF, from the domain of machine 
learning, has been proposed for prediction, feature selection, and feature ranking in fields related 
to computational biomedicine [118]. RF shows excellent performance, even if decision 
boundaries are non-functional and involve complex high-order interaction effects. Furthermore, 
it avoids over-fitting even when most predictive features are noise. It is well suited for datasets 
where the number of features (OTUs) is orders of magnitude larger than the number of samples 
[119, 120]. 
For this study, we first pre-processed the data by dropping features with zero variance, 
and then we incorporated a parameter-space mapping algorithm to determine the model 
parameters for RF. Using these parameters (Ntree: 10000, Mtry: 12, ISS: False), RF constructed 
an ensemble of classification or regression trees from bootstrap samples of the data.  Each tree 
was fit using a random subset of features to define the best split at each node that allowed for 
trees to be fit in a lower dimension without introducing additional bias while the averaging of 
these trees removed variance from the prediction.  The “out-of-bag” (OOB) samples—i.e., 
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observations left out of the bootstrap samples—were used to estimate prediction error of trees.  
The variable importance measure (VIM) for feature Xj, was the difference in prediction error 
caused by randomly permuting the Xj OOB sample values.  Therefore, VIM represents the 
benefit of having a feature included in a tree compared to random noise. For feature ranking, the 
advantage of the RF permutation-accuracy measure compared to univariate filtering measures is 
that it captures the impact of each feature individually, as well as conditional importance 
stemming from multivariate interactions between the features [121]. 
These steps were followed by stability analysis and feature permutation to identify a 
minimal optimal set of highly relevant OTUs. The original feature set was extended with a 
permuted set of features, called shadow features.  For each unique feature, a shadow feature was 
created by randomly permuting the values from all observations.  By creating these randomly 
permuted features X'j, we broke their original associations with the response.  When permuted 
features are used for prediction, the prediction accuracy decreases substantially.  Thus a 
reasonable measure for feature relevance is the likelihood that a feature has a higher mean VIM 
than its shadow feature. It is estimated by the p-value of a one-sided t-test between each feature 
and the shadow with the highest mean VIM. We found this to be a more conservative estimator 
of model performance than if the model were fitted and tested using all of the samples.   
 
5.2.4. Statistical Analyses. 
Data from gene expression and animal studies were analysed using either a one-way 
analysis of variance (ANOVA) model to compare different ligand effects, a two-way-ANOVA 
model to compare time-dependent changes. For every main effect that was statistically 
significant at =0.05, pairwise t-tests were conducted to determine which ligand or inhibitor 
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treatment levels were significantly different from each other. For these t-test, the Bonferroni 
correction was employed to control the experimentwise type I error rate at α=0.05 followed by 
Bonferroni post hoc test using GraphPad Prism version 6 for Windows, (GraphPad Software, La 




5.3.1. CE+BZA does not affect overall microbiota diversity but influences particular bacterial 
genera that might affect half-life of estrogenic compounds in the body. 
We performed microbiome analysis using fecal and cecal samples from the same 
animals. PCoA analysis using unweighted UniFrac data showed that both fecal and cecal 
populations assumed distinct composition after treatment with different estrogens (Fig 5.1A, 
5.1B).  The relative abundance of samples revealed small changes in both fecal and cecal 
bacterial phyla (Fig 5.1C). We also used ANOVA on each bacteria genus, to understand whether 
the variations among percentages of bacteria found in each treatment group were significantly 
different. This analysis showed that the two indicators- number of species and Shannon index - 
for either cecal or fecal samples, were not significantly different between the different groups 
(Fig 5.1D, 5.1E).  
Since we did not see statistically different changes in bacterial phyla, we focused on the 
changes in individual OTU. Using ERF method, we integrated metabolite and microbiome 
datasets to obtain a higher-level understanding of the metabolic circuitries and gut microbiome 
composition that are regulated by different estrogens. This analysis enabled us to identify liver 
weight, two fecal bacterial genus-Akkermansia and Anaerotruncus and several metabolites as 
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features that could discriminate between low and high percent weight gain samples (Fig 5.2A). 
Further analysis revealed that Fecal Akkermansia and blood glucuronic acid levels were highly 
correlated with liver weight and percent weight change (Fig 5.2B, 5.2C) and both features were 
downregulated in CE+BZA treatment group (Fig 5.2D). 
 
5.4. DISCUSSION 
Enterohepatic circulation is the circulation of bile and other drugs from the liver to the 
bile and finally into the small intestine. Large amounts of endogenous and exogenous estrogens 
go through enterohepatic circulation and considerable amounts are excreted in the bile [122]. In 
fact only about 10% of the injected estrogens are recovered in the urine and the rest goes through 
this recycling through enterohepatic circulation.  Since majority of estrogens that we administer 
through minipump is recycled by enterohepatic circulation and goes through the gut it is highly 
likely that these exogenous estrogens directly interact with the microbiota and affect their 
composition. In addition, previous studies also show that estrogen deficiency induce intestinal 
inflammation and permeability that is reversed by estrogen administration [123, 124]. So, the 
final impact of these exogenous estrogens on gut microbiome and gut-liver axis health is 
probably a combination of these two; enterohepatic circulation and direct effects of estrogens on 
intestine.   
Our results suggest that estrogens and the microbiota may act together to regulate weight 
gain and lipid deposition [125]. Estrogen-like compounds, when administered through 
minipumps or injection, may promote the proliferation and growth of certain types of bacteria as 
they go through enterohepatic circulation. It may be possible that the microbiota metabolizes 
endogenous, synthetic or dietary estrogens to produce novel ER ligands that can also be used to 
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mitigate symptoms associated with menopause and obesity. Alternatively, the microbiota may be 
manipulated to change half-life and properties of estrogens so that they could maintain metabolic 
function but reduce the risk of other diseases such as breast cancer. Exogenous estrogens are 
conjugated in the liver that will increase their excretion. However, as the bacteria in the gut 
deconjugate estrogens (e.g. β-glucuronidase activity) these estrogens will be taken up into 
circulation and thus will stay in the body longer. In fact, one of the genera that we identified in 
our analysis, Akkermansia, expresses enzymes such as β-glucuronidase. β-Glucuronidase makes 
these bacteria capable of metabolizing conjugated estrogens in the intestine and affecting 
residence time of estrogens in the blood. In fact plasma glucuronic acid levels correlate with 
Akkermansia.  
Overall our findings suggest that synthetic estrogens decrease levels of bacteria that can 
metabolize estrogens in the gut and thus decrease the half-life of endogenous and exogenous 
estrogens in the body. Based on our findings, with the long term estrogen treatment, certain 
bacterial species that are required to deconjugate estrogens are lost in the gut. Our observations 
suggest that the impact of current hormone replacement therapies may be manipulated and 
dosage might be optimized if they are supplemented in combination with probiotic supplements. 
These findings could possibly provide a more holistic treatment approach against 




CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 CONCLUSION 
 The collection of studies presented in this thesis show how novel and synthetic estrogenic 
ligands, such as PaPE-1 and CE+BZA combination can influence metabolism at cellular, 
organism and microbiota levels.  In particular, PaPE-1 modulated metabolic pathways indicative 
of a healthier liver compared to controls in two mouse models. CE+BZA treatment was also very 
promising in decreasing liver weights and reducing lipid accumulation in ovariectomized mice 
fed a high fat diet. PaPE-1 and CE+BZA treatments reduce lipid accumulation in the liver and 
attenuate certain inflammatory responses which we investigated through histology, 
transcriptomic, metabolomics analysis. Additionally, microbiome analysis data from animals that 
were treated with CE+BZA treatment suggests a potential estrogen and microbiome crosstalk 
where treatment significantly changed the composition of several genera in the gut microbiota. 
 Based on our results, there is a potential for novel and synthetic therapies for 
postmenopausal women that may reduce their risk for NAFLD. PaPE-1 and CE+BZA are 
examples of estrogenic treatments that modulate metabolic pathways in order to promote a 
healthier liver. The gut-liver axis may also be a therapeutic target for the prevention of NAFLD 
in postmenopausal women. Though more research is needed in the mechanism of estrogen and 
gut microbiota crosstalk, this research points to promising associations that should be explored 
further. 
6.2 FUTURE DIRECTIONS  
Since PaPE-1 is tissue selective and has metabolic benefits without stimulating 
reproductive tissues, the potential for PaPE-1 to be a pharmacological therapy for 
postmenopausal women could be explored. One future direction of this work is to test the effects 
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of PaPE-1 on many different human cell line and animal models associated with metabolic 
syndrome. Ideally, clinical studies could be conducted as well, which could include 
postmenopausal volunteers. These may more accurately show metabolic effects of PaPE-1 on 
humans. 
CE+BZA is already an FDA approved pharmacological drug for the use in 
postmenopausal women with a uterus. Though some of the metabolic effects of CE+BZA have 
been studied, more research could be done regarding the mechanism between CE+BZA and gut 
microbiota interaction. Therefore, another future direction of this work would be to directly 
investigate the glucuronidase activity in certain bacteria such as Akkermansia and others that 
may influence estrogen metabolism and modulate the half-life of estrogens in the body. More 
specifically, estrogen glucuronides could be tested with these bacteria to assess their ability to 
cleave glucuronide. Additionally, estrogens could be metabolized by human microsomes to more 
accurately produce estrogen metabolites in the body and then further incubated with the bacteria. 
These studies could give a more holistic overview of the interaction between estrogens and the 








Fig 1.1 Gut health is linked to liver health. In a normal gut, microbes and byproducts stay within 
the lumen of the intestine. In an unhealthy microbes and byproducts may be in dysbiosis or may 
leak contents that reach the liver through the portal vein. Microbial byproducts can lead to 




Fig. 2.1. Potential Microbiome and Estrogen Interaction. Estrogens inherent in the body or from 
the diet may be metabolized by gut microbes and produce estrogenic metabolites that affect host 







Fig. 3.1. Body and organ masses of PaPE-1 treated DIO and ob/ob mice. (A) PaPE-1 prevents 
weight gain caused by HFD but is not significant in ob/ob mice. (B) PaPE-1 prevents fat mass 
increase caused by HFD but not ob/ob mice. (C) Liver weight of both DIO and ob/ob mice show 
that PaPE-1 is very effective at decreasing liver weight increase caused by HFD or leptin 







Fig. 3.2. Lipid accumulation in mouse liver tissue and human hepatocyte cells (HepG2) after 
PaPE-1 treatment. (A) H+E and Oil Red O staining of mouse liver tissue show decreased lipid 
accumulation after both estrogenic E2 and PaPE-1 treatments. (B) Quantification of lipid droplet 
size by Fiji correlate to show PaPE-1 is effective at decreasing lipid drop size in mouse liver 
tissue. (C) Lipid accumulation in HepG2 cells after PaPE-1 and E2 treatment also appear to 
decrease lipid accumulation. (D) Fiji analysis of corrected total cell fluorescence shows PaPE-1 







Fig. 3.3. Gene expression of DIO and ob/ob mice treated with PaPE-1. (A) RNA-seq data was 
clustered using Cluster 3.0 and visualized as a heat map using Java TreeViewer. (B) PaPE-1 up-
regulates and down-regulates common as well as distinct groups of genes compared to E2. (C) 
qPCR validation of selected genes Fasn and Srebp1c correlate RNA-seq data. Data for Pparγ 
were not normally distributed and were analyzed using Mann Whitney test for nonparametric 
data (D) qPCR of FASN and SREBP1c in HepG2 human cell lines correspond to mouse model 
qPCR data (E) Volcano plots of gene expression data show several genes significantly affected 








Fig. 3.4. Blood plasma metabolites of PaPE-1 treatment in DIO and ob/ob mice. (A) Metabolites 
were identified by the GC-MS analysis and incorporated into a heatmap for visualization. 
Metabolites were clustered using Cluster 3.0 and visualized using Java TreeView.  (B) PaPE-1 
affected several metabolites similarly to E2 treatment. (C) There were many metabolites distinct 






Fig. 3.5. Integrated pathway analysis of PaPE-1 treatment in DIO and ob/ob mice. (A) Integrated 
pathway analysis using Metaboanalyst showed common metabolic pathways effected by PaPE-1 
treatment in both DIO and ob/ob models. Top common pathways between the two mouse models 
show retinol metabolism and drug metabolism-cytochrome p450 were significantly modulated. 
(B) Glutathione metabolism pathway is shown as an example of a significant pathway effected. 
Red denotes modulation in DIO mice and blue denotes modulation in ob/ob mice. GO term 
analysis of genes and metabolites of (C) DIO and (D) ob/ob models show several pathways 
affected by PaPE-1 treatment which show a possible reduction in inflammation and oxidative 








Fig. 4.1. CE+BZA combination decreases ovariectomy-associated weight gain and lipid 
deposition without stimulating reproductive tissue. (A) Total body weight change was 
significantly less in E2, CE only, and CE+BZA group compared with the control. CE+BZA had 
the greatest effect on body weight change (P < 0.001) after 6 weeks of treatment. (B) Fat mass 
was analysed using EchoMRI at four weeks of treatment. All treatment groups had fat masses 
significantly lower than the control. CE only and CE+BZA groups had fat masses comparable to 
E2 treatment. (C) Uterus and (D) liver were harvested at the end of 6 weeks and weighed. 
CE+BZA treated mice had the lowest liver weight compared to vehicle. Mice treated with BZA 
only and CE+BZA did not have increased uterus weight. All treatment groups were normally 
distributed. Statistical significance was established at α = 0.05. Pairwise t tests with a Bonferroni 
correction were used to identify treatments that were significantly different from each other (*P 













Fig. 4.2. Lipid accumulation is decreased in mouse liver tissue after CE+BZA treatment. (A) 
H+E and Oil Red O staining of mouse liver tissue show decreased lipid accumulation after all 
estrogenic E2, CE only, BZA only, and CE+BZA treatments. (B) Quantification of lipid droplet 










Fig. 4.3. E2, CE only, BZA only, and CE+BZA regulate common as well as distinct groups of 
genes in mice liver. Mice were treated with vehicle E2, CE only, BZA only, or CE+BZA for 6 
weeks. (A) RNA was isolated from the liver and RNA-seq was performed. Regulated genes are 
considered to be those with P < 0.05 and expression fold change >2 (n = 3 biological replicates). 
(B) Each group had common and distinct upregulated and downregulated genes. (C) qPCR 
analysis of selected genes validate RNA-seq results for Cfd and Pparɣ. All genes are decreased 
in CE+BZA treated mice which matched patterns of expression. Statistical significance was 
established at α = 0.05. Data for Cfd was normally distributed. This was analyzed using pairwise 
t tests with a Bonferroni correction to identify treatments that were significantly different from 
each other (*P < 0.05, **P < 0.01, ****P <0.0001). Data for Pparg were not normally distributed 
and were analyzed using Mann Whitney test for nonparametric data (*P < 0.05, **P < 0.01, 
****P <0.0001). (D) Volcano plots of gene expression data show several genes significantly 






Fig. 4.4. Whole metabolite analysis of plasma from animals that were treated with different 
ligands. Blood was taken at the time of harvest, six weeks after treatment. Metabolites were 
identified by the GC-MS analysis. (A) Metabolomic data was clusted and visualized as a 
heatmap using Java TreeView. (B) E2 and CE+BZA had distinct and common metabolites. (C) 
Common metabolites are shown to include tetradecanoic acid and coprostan-3-ol which had 
reduced and increased abundance respectively (D) Tetradecanoic acid relative concentration in 
blood plasma is significantly decreased in all estrogenic treatments. Coprostan-3-ol relative 






Fig. 4.5. Integrated pathway analysis show inflammatory and fatty acid pathways affected by 
CE+BZA treatment. Genes and metabolites were incorporated into integrated pathway analysis 
through Cytoscape on the ClueGO application. (A) Downregulated and (B) upregulated GO 






Fig. 5.1. Microbiome analysis of CE+BZA treated mice showed no significant overall change in 
microbiota diversity. Cecal (A) and fecal (B) PCoA plots based on unweighted UniFrac distance 
show that diversity is less variable in CE+BZA treated mice. (C) Overall phyla from cecal and 
fecal samples also show similar diversity. (D) # species and (E) Shannon index showed no 






Fig. 5.2. Identification of important bacterial taxa and plasma metabolites that correlate with 
lowest % weight gain. (A) Features from blood, cecal, and fecal samples were analysed for 
association with weight gain. Percent weight gain is affected by several metabolites but also the 
abundance of Akkermansia, Anaerotruncus, and Dehalobacterium species in fecal and cecal 
samples. Detailed association data for samples (n=4) were shown for several features’ 
association against weight gain (B) and Akkermansia (C). Fecal Akkermansia and blood 
glucuronic acid levels were highly correlated with liver weight and percent weight change. (D) 
The levels of Akkermansia and glucuronic acid were shown for each treatment. Both features 
were downregulated in CE+BZA treated mice. One-way ANOVA was used to identify the 
statistically significant difference in metabolite or bacteria level due to ligand treatment.  * P < 
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